Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit
24 Diciembre 2024 - 6:00AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage
biotechnology company dedicated to creating small molecule drugs
for virology and immunology indications, today announced that the
United States District Court of Massachusetts (“the Court”) has
issued a ruling on a summary judgment motion filed by Pfizer, Inc.
in connection with Enanta’s patent infringement lawsuit seeking
damages for infringement of U.S. Patent No. 11,358,953 (“the ’953
Patent”) in the manufacture, use and sale of Pfizer’s COVID-19
antiviral, Paxlovid™ (nirmatrelvir tablets; ritonavir tablets).
The Court issued a summary judgment decision granting Pfizer’s
motion that the ‘953 Patent is invalid. In its decision, the Court
also denied Enanta’s partial motion for summary judgment of
infringement as moot in light of its allowance of summary judgment
on invalidity. Enanta plans to appeal the decision to the Court of
Appeals for the Federal Circuit.
"The U.S. patent system and its protection of important
innovations have enabled the robust development of new medicines
and spurred growth in the biotechnology industry. We are proud of
the impact our strong history of drug discovery work with protease
inhibitors has had on antiviral treatments and the thousands of
patients that have been treated with therapies using our patented
inventions,” said Jay R. Luly, Ph.D., President and Chief Executive
Officer of Enanta Pharmaceuticals, Inc. “We are disappointed with
the Court’s ruling. We believe strongly in the merits of our case,
and, through the appeal process, we will continue to defend our
inventions from unlawful infringement.”
Enanta maintains its commitment to avoid attempting to impede
the production, sale or distribution of Paxlovid.
About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug
discovery capabilities to become a leader in the discovery and
development of small molecule drugs with an emphasis on indications
in virology and immunology. Enanta’s clinical programs are
currently focused on respiratory syncytial virus (RSV) and its
earlier-stage immunology pipeline aims to develop treatments for
inflammatory diseases by targeting key drivers of the type 2 immune
response, including KIT and STAT6 inhibition.
Glecaprevir, a protease inhibitor discovered by Enanta, is part
of one of the leading treatment regimens for curing chronic
hepatitis c virus (HCV) infection and is sold by AbbVie in numerous
countries under the tradenames MAVYRET® (U.S.) and MAVIRET®
(ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s
royalties from HCV products developed under its collaboration with
AbbVie contribute ongoing funding to Enanta’s operations. Please
visit www.enanta.com for more information.
Forward-Looking Statements
This press release contains forward-looking statements,
including statements with respect to Enanta’s suit against Pfizer,
Inc. in the United States District Court for the District of
Massachusetts seeking damages for patent infringement. Statements
that are not historical facts are based on management’s current
expectations, estimates, forecasts and projections about Enanta’s
business and the industry in which it operates and management’s
beliefs and assumptions. The statements contained in this release
are not guarantees of future performance and involve certain risks,
uncertainties and assumptions, which are difficult to predict.
Therefore, actual outcomes and results may differ materially from
what is expressed in such forward-looking statements. Important
factors and risks that may affect actual results include: Enanta is
competing to develop intellectual property in areas of
small-molecule drug development that are highly competitive; issued
patents, including the patent at issue in the Pfizer litigation,
could be found invalid or unenforceable if challenged in court and
could be costly to defend and be a distraction for Enanta’s senior
management and scientific personnel; intellectual property
litigation may lead to unfavorable publicity that harms Enanta’s
reputation and causes the market price of its common stock to
decline; and other risk factors described or referred to in “Risk
Factors” in Enanta’s Form 10-K for the fiscal year ended September
30, 2024 and other periodic reports filed more recently with the
Securities and Exchange Commission. Enanta cautions investors not
to place undue reliance on the forward-looking statements contained
in this release. These statements speak only as of the date of this
release, and Enanta undertakes no obligation to update or revise
these statements, except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241224565771/en/
Media and Investors: Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024